Pharmaceutics (Apr 2023)

The Pillars for Renal Disease Treatment in Patients with Type 2 Diabetes

  • Jessica Kearney,
  • Luigi Gnudi

DOI
https://doi.org/10.3390/pharmaceutics15051343
Journal volume & issue
Vol. 15, no. 5
p. 1343

Abstract

Read online

The diabetes epidemic and the increasing number of patients with diabetic chronic vascular complications poses a significant challenge to health care providers. Diabetic kidney disease is a serious diabetes-mediated chronic vascular complication and represents a significant burden for both patients and society in general. Diabetic kidney disease not only represents the major cause of end stage renal disease but is also paralleled by an increase in cardiovascular morbidity and mortality. Any interventions to delay the development and progression of diabetic kidney disease are important to reduce the associated cardiovascular burden. In this review we will discuss five therapeutic tools for the prevention and treatment of diabetic kidney disease: drugs inhibiting the renin–angiotensin–aldosterone system, statins, the more recently recognized sodium-glucose co-transporter-2 inhibitors, glucagon-like peptide 1 agonists, and a novel non-steroidal selective mineralocorticoid receptor antagonist.

Keywords